Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy

References

• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466. PMID:20525992.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627. PMID:26028407.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:10.1056/NEJMoa1501824. PMID:25891174.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa1104621. PMID:21639810.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690. PMID:22658127.
   PubMed Web of Science ®Google Scholar
• Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416–421. doi:10.1097/SLA.0000000000000869. PMID:25115417.
   PubMed Web of Science ®Google Scholar
• Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 54(2):94–109. doi:10.3322/canjclin.54.2.94. PMID:15061599.
   PubMed Web of Science ®Google Scholar
• Pollack SM, He Q, Yearley JH, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. May 2017:1–14.
   Google Scholar
• Liu C-YC-L, Yen C, Chen W-M, Chen TH, Chen PC, Wu HT, Shiau CY, Wu YC, Liu CL, Tzeng CH. Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol. 2010;17(8):2102–2111. doi:10.1245/s10434-010-0997-0. PMID:20217247.
   PubMed Web of Science ®Google Scholar
• Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2000;48(4):1051–1058. doi:10.1016/S0360-3016(00)00753-7. PMID:11072162.
   PubMed Web of Science ®Google Scholar
• Delaney TF, Kepka L, Goldberg SI, Hornicek FJ, Gebhardt MC, Yoon SS, Springfield DS, Raskin KA, Harmon DC, Kirsch DG, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys. 2007;67(5):1460–1469. doi:10.1016/j.ijrobp.2006.11.035. PMID:17394945.
   PubMed Web of Science ®Google Scholar
• Tiong SS, Dickie C, Haas RL, O'Sullivan B. The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer Biol Med. 2016;13(3):373–383. doi:10.20892/j.issn.2095-3941.2016.0028. PMID:27807504.
   PubMed Web of Science ®Google Scholar
• Larrier NA, Czito BG, Kirsch DG. Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. Surg Oncol Clin N Am. 2016;25(4):841–860. doi:10.1016/j.soc.2016.05.012. PMID:27591502.
   PubMed Web of Science ®Google Scholar
• O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–2241. doi:10.1016/S0140-6736(02)09292-9. PMID:12103287.
   PubMed Web of Science ®Google Scholar
• Schaefer I-M, Hornick JL, Barysauskas CM, Raut CP, Patel SA, Royce TJ, Fletcher CDM, Baldini EH. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017;98(2):375–383. doi:10.1016/j.ijrobp.2017.02.087. PMID:28463157.
   PubMed Web of Science ®Google Scholar
• Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, Mandard AM, Vilain MO, Jacquemier J, Duplay H, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14(3):869–877. doi:10.1200/JCO.1996.14.3.869. PMID:8622035.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251(3):506–511. doi:10.1097/SLA.0b013e3181cf87fa. PMID:20130465.
   PubMed Web of Science ®Google Scholar
• Italiano A, Le Cesne A, Mendiboure J, Blay JY, Piperno-Neumann S, Chevreau C, Delcambre C, Penel N, Terrier P, Ranchere-Vince D, et al. Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. Cancer. 2014;120(21):3361–3369. doi:10.1002/cncr.28885. PMID:25042799.
   PubMed Web of Science ®Google Scholar
• Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–1689. doi:10.1200/JCO.1996.14.5.1679. PMID:8622088.
   PubMed Web of Science ®Google Scholar
• Smith HG, Memos N, Thomas JM, Smith MJF, Strauss DC, Hayes AJ. Patterns of disease relapse in primary extremity soft-tissue sarcoma. Br J Surg. 2016;103(11):1487–1496. doi:10.1002/bjs.10227. PMID:27503444.
   PubMed Web of Science ®Google Scholar
• Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;18(6):604–610.
   Google Scholar
• Burgess M, Tawbi H. Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol. 2015;16(6):26. doi:10.1007/s11864-015-0345-5. PMID:25975445.
   PubMed Web of Science ®Google Scholar
• Lim J, Poulin NM, Nielsen TO. New strategies in sarcoma: Linking genomic and immunotherapy approaches to molecular subtype. Clin Cancer Res. 2015;21(21):4753–4759. doi:10.1158/1078-0432.CCR-15-0831. PMID:26330427.
   PubMed Web of Science ®Google Scholar
• Mitsis D, Francescutti V, Skitzki J. Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma. 2016;2016:9757219. doi:10.1155/2016/9757219. doi:10.1155/2016/9757219. PMID:27703409.
   PubMedGoogle Scholar
• Angelo SPD. Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. ASCO Educ B. 2016:e558–564.
   Google Scholar
• Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, Rosen G. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6(1):24. doi:10.1186/s13569-016-0064-0. PMID:28042471.
   PubMedGoogle Scholar
• Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature12213. PMID:23770567.
   PubMed Web of Science ®Google Scholar
• Melissa Amber Burgess, Vanessa Bolejack, Brian Andrew, Van Tine, Scott Schuetze, James Hu, Sandra P. D'Angelo, Steven Attia, Dennis A. Priebat, Scott H. Okuno, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. J Clin Oncol. 2017;35( suppl; abstr 11008).
   Web of Science ®Google Scholar
• Kalbasi A, June C, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123(7):2756–2763. doi:10.1172/JCI69219. PMID:23863633.
   PubMed Web of Science ®Google Scholar
• Tang C, Wang X, Soh H. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2(9):831–838. doi:10.1158/2326-6066.CIR-14-0069. PMID:25187273.
   PubMed Web of Science ®Google Scholar
• Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, Chang JY, Hahn SM, Welsh JW. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 22(2):130–137. doi:10.1097/PPO.0000000000000181. PMID:27111909.
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Haas RL, Bovée JVMG, Terrier P, Lazar A, Messiou C, LePechoux C, Hartmann W, Collin F, Fisher C, et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur J Cancer. 2016;53:84–95. doi:10.1016/j.ejca.2015.09.021. PMID:26700077.
   PubMed Web of Science ®Google Scholar
• Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, et al. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination. Eur J Cancer. 2016;56:37–44. doi:10.1016/j.ejca.2015.12.008. PMID:26802529.
   PubMed Web of Science ®Google Scholar
• Picci P, Böhling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, Ruggieri P, Manfrini M, Ferraro A, Casadei R, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15(4):1553–1559. doi:10.1200/JCO.1997.15.4.1553. PMID:9193352.
   PubMed Web of Science ®Google Scholar
• Mullen JT, Hornicek FJ, Harmon DC, Raskin KA, Chen YL, Szymonifka J, Yeap BY, Choy E, DeLaney TF, Nielsen GP. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014;120(23):3676–3682. doi:10.1002/cncr.28945. PMID:25081640.
   PubMed Web of Science ®Google Scholar
• Menendez LR, Ahlmann ER, Savage K, Cluck M, Fedenko AN. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma. Clin Orthop Relat Res. 2007;455:219–224. doi:10.1097/01.blo.0000238864.69486.59. PMID:17016226.
   PubMed Web of Science ®Google Scholar
• Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–3209. doi:10.1200/JCO.2001.19.13.3203. PMID:11432887.
   PubMed Web of Science ®Google Scholar
• MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, Connell PP. Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(4):1147–1153. doi:10.1016/j.ijrobp.2009.03.015. PMID:19577863.
   PubMed Web of Science ®Google Scholar
• Schilham MW, Marie A, Jansen C. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66(1):119–128. doi:10.1007/s00262-016-1925-3. PMID:27853827.
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Akiyama R, Huang RR, Shintaku IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N, et al. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunol Res. 2017;5(2):118–126. doi:10.1158/2326-6066.CIR-16-0148. PMID:28039162.
   PubMed Web of Science ®Google Scholar
• Kostine M, Cleven AHG, Miranda NFCC De, Italiano A, Bovée JVMG. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol. 2016;29(9):1028–1037. doi:10.1038/modpathol.2016.108. PMID:27312065.
   PubMed Web of Science ®Google Scholar
• Angelo SPD, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma. Hum Pathol. 2015;46(3):357–365. doi:10.1016/j.humpath.2014.11.001. PMID:25540867.
   PubMed Web of Science ®Google Scholar
• Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas. PLoS One. 2013;8(12):1–9. doi:10.1371/journal.pone.0082870..
   Web of Science ®Google Scholar
• Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, et al. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology. 2017;6(3):1–9. doi:10.1080/2162402X.2017.1279777..
   Web of Science ®Google Scholar
• Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16(1):434. doi:10.1186/s12885-016-2451-6. PMID:27393385.
   PubMedGoogle Scholar
• Wolchok J, Kluger H, Callahan M. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2013;369(2):122–133. doi:10.1056/NEJMoa1302369. PMID:23724867.
   PubMed Web of Science ®Google Scholar
• Filatenkov A, Baker J, Mueller AMS, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–3739. doi:10.1158/1078-0432.CCR-14-2824. PMID:25869387.
   PubMed Web of Science ®Google Scholar
• Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A, Boehmer Lv, Broek Mv. у-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One. 2011;6(11):e28217. doi:10.1371/journal.pone.0028217. PMID:22140550.
   PubMed Web of Science ®Google Scholar
• Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, van den Broek M. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res. 2013;19(17):4843–4853. doi:10.1158/1078-0432.CCR-13-0352. PMID:23861514.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313. PMID:24382348.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–5388. doi:10.1158/1078-0432.CCR-09-0265. PMID:19706802.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931. doi:10.1056/NEJMoa1112824. PMID:22397654.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012;5(6):404–407. doi:10.1593/tlo.12280. PMID:23323154.
   PubMed Web of Science ®Google Scholar
• Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–372. doi:10.1158/2326-6066.CIR-13-0115. PMID:24563870.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780. doi:10.4161/onci.28780. PMID:25083318.
   PubMed Web of Science ®Google Scholar
• Demaria S, Golden EB, Formenti SC. Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1(9):1325. doi:10.1001/jamaoncol.2015.2756. PMID:26270858.
   PubMed Web of Science ®Google Scholar